FDA approves Celgene drug for pancreatic cancer

Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer.

In experimental trials, the drug extended the lives of patients by a little less than two months more than those treated with the current standard drug.

Abraxane is already approved to treat and a type of lung cancer. It accounted for $155 million in revenue for Celgene in the second quarter.

Pancreatic cancer is considered especially deadly and hard to treat. It typically causes few symptoms until it has spread enough that it can't be surgically removed.

The National Cancer Institute estimates about 45,000 patients will be diagnosed and about 38,000 will die from the disease this year.

Related Stories

Abraxane approved to treat advanced lung cancer

date Oct 14, 2012

(HealthDay)—Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration—in combination with the drug carboplatin—to treat advanced or spreading non-small cell lung ...

Recommended for you

Spicy treatment the answer to aggressive cancer?

date Jul 03, 2015

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

date Jul 02, 2015

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

date Jul 02, 2015

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.